rs376403182
Variant summary
Our verdict is Likely benign. Variant got -3 ACMG points: 0P and 3B. BP4_ModerateBP6
The NM_058216.3(RAD51C):c.7G>A(p.Gly3Arg) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000335 in 1,614,020 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 15/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_058216.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -3 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000263 AC: 4AN: 152224Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000318 AC: 8AN: 251294Hom.: 0 AF XY: 0.0000221 AC XY: 3AN XY: 135860
GnomAD4 exome AF: 0.0000342 AC: 50AN: 1461796Hom.: 0 Cov.: 32 AF XY: 0.0000358 AC XY: 26AN XY: 727200
GnomAD4 genome AF: 0.0000263 AC: 4AN: 152224Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 74366
ClinVar
Submissions by phenotype
Hereditary cancer-predisposing syndrome Uncertain:1Benign:3
This missense variant replaces glycine with arginine at codon 3 of the RAD51C protein. Computational prediction tool suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). Functional studies have shown that this variant could restore normal mitomycin C sensitivity and RAD51 foci formation in the RAD51C mutant cells (PMID: 20400964). This variant has been reported in individuals affected with breast and/or ovarian cancer (PMID: 20400964, 25470109, 26261251, 26976419). This variant has been identified in 11/282672 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
- -
- -
not provided Uncertain:1
In silico analysis supports that this missense variant does not alter protein structure/function; Published functional studies demonstrate no damaging effect: cell survival and RAD51 foci formation similar to wild-type (Meindl et al., 2010); Observed in individuals with breast, ovarian, and other cancers (Scheckenbach et al., 2014; Song et al., 2015; Tung et al., 2016); This variant is associated with the following publications: (PMID: 24315737, 26261251, 23117857, 26976419, 25470109, 21537932, 28829762, 33471991, 20400964) -
Fanconi anemia complementation group O Uncertain:1
This sequence change replaces glycine, which is neutral and non-polar, with arginine, which is basic and polar, at codon 3 of the RAD51C protein (p.Gly3Arg). This variant is present in population databases (rs376403182, gnomAD 0.007%). This missense change has been observed in individual(s) with breast cancer, ovarian cancer and head and neck squamous cell carcinoma (PMID: 20400964, 24315737, 25470109, 26261251, 26976419). ClinVar contains an entry for this variant (Variation ID: 184411). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. Experimental studies have shown that this missense change does not substantially affect RAD51C function (PMID: 20400964). RNA analysis performed to evaluate the impact of this missense change on mRNA splicing indicates it does not significantly alter splicing (Invitae). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
not specified Benign:1
Curator: Arleen D. Auerbach. Submitter to LOVD: Johan den Dunnen. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at